CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: **Outcome of Board Meeting held on November 14, 2026**

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and such other rules and regulations, if and as may be applicable, we hereby inform that the Board of Directors of Anondita Medicare Limited ("the Company"), at its meeting held today i.e., Saturday, November 14, 2026 at 04:00 P.M at the corporate office situated at D-001, Sector 80, Gautam Buddha Nagar, Noida, Uttar Pradesh-201305, have, inter-alia, considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the half year ended September 30, 2026

The said financial results have been limited reviewed by the Statutory Auditors of the Company and the Limited Review Report issued thereon is enclosed herewith

Pursuant to Regulation 33 and 30 of the Listing Regulations and applicable LODR Regulations, if any, we are enclosing herewith the following:

1. Unaudited Financial Results (Standalone and Consolidated) for the half year ended September 30, 2026 along with limited review report by the Statutory Auditors of the Company
2. Statement of deviation / Variation in utilization of Funds raised through IPO, Preferential issue of Convertible warrants to promoter and promoter group; and Right issue.
3. Disclosure pursuant to Related Party Transaction.

The meeting of the Board of Directors commenced at 04:00 P.M. (IST) and concluded at 06:00 P.M (IST).

This is for your information and record, and this intimation is also being uploaded on the Company's website at the link https://anonditamedicare.com/.

Thanking you,
Yours Truly
For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Bhawna Bisht
Company Secretary and Compliance Officer
Membership No. A70843

Encl: As Above



Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-42171194 Mob : 9810247478
E-mail : jainchopra.company@gmail.com

Independent Auditor's Limited Review Report on unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015

To,
The Board of Directors of Anondita Medicare Limited

We have reviewed the accompanying statement of unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2026. This Financial statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Chopra & Company
Chartered Accountants
FR No. 002198N

Rajesh Kumar

Rajesh Kumar
Partner
M.No. 501860

JAIN CHOPRA & COMPANY ★ NEW DELHI ★ CHARTERED ACCOUNTANTS

Place: New Delhi
Date: 14-11-2026

UDIN: 26501860EINZZV2699

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

UNAUDITED STANDALONE FINANCIAL STATEMENT AS AT 30 SEPTEMBER, 2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)
I. EQUITY AND LIABLITIES			
1. Shareholders' funds			
(a) Share Capital	1,904.48	1,808.66	1,808.66
(b) Reservs and surplus	19,930.17	7,963.81	9,494.38
(c) Money received against share warrants	739.58		
2. Share application money pending allotment			
3. Non - current liabilities			
(a) Long-term borrowings	4,248.49	1,307.40	2,359.62
(b) Deferred Tax Liability (net)	169.83	24.06	193.52
(c) Other Long term liabilities			
(d) Long Term Provision	26.66	15.13	17.80
4. Current liabilities			
(a) Short-term borrowings	2,533.47	1,738.22	967.80
(b) Trade payables			
A) Total outstanding dues of micro enterprises and small enterprises	164.22	153.00	141.23
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,041.38	323.64	652.64
(c) Other current liabilities	214.17	265.97	193.85
(d) Short-term Provisions	894.64	732.51	463.62
Total	**31,867.08**	**14,332.39**	**16,293.12**
ASSETS			
1) Non Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	5,295.77	1,275.48	3,907.98
(ii) Intangible assets			
(iii) Capital Work In Progress	7,420.55	1,522.08	4,149.50
(iv) Intangible assets under development			
(b) Non-current Investments	351.58	351.58	351.58
(c) Deferred tax assets (net)			
(d) Long-term loans and advances	317.06	37.66	220.79
(e) Other non - current assets	0.12	0.20	0.16
2) Current Assets			
(a) Current investments			
(b) Inventories	2,043.75	1,103.36	1,349.14
(c) Trade receivables	4,821.52	3,321.36	3,798.80
(d) Cash and Cash Equivalents	9,145.75	3,628.28	954.10
(e) Short-term loans and advances	1,790.40	2,360.94	1,109.75
(f) Other current assets	680.58	731.45	451.32
Total	**31,867.08**	**14,332.39**	**16,293.12**

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001 Sector 80 Noida U.P

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

UNAUDITED STANDALONE STATEMENT OF PROFIT & LOSS AS AT 30 SEPTEMBER, 2026

Amount in Rs.Lakhs unless stated otherwise

PARTICULARS	For the half year ended			For the year ended	
	As at Sept 30,2026 (Unaudited)	As at March 31, 2026 (Audited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I. Revenue from operations	5,786.31	6,404.56	4,765.06	11,169.62	6,051.52
II. Other Income	90.21	100.35	75.56	175.91	36.38
III. Total Income (I +II)	5,876.52	6,504.91	4,840.62	11,345.53	6,087.90
IV. Expenses:					
Cost of Materials Consumed	2,774.37	2,867.91	2,353.22	5,221.13	3,376.69
Purchase of Stock-in-Trade	-	-			
Change in inventories of finished goods, Work in progress and Stock in Trade	(542.12)	(156.25)	(186.94)	(343.19)	(202.97)
Employee benefit expense	426.87	391.93	271.06	662.99	483.66
Financial costs	231.37	166.95	181.32	348.27	289.46
Depreciation and amortization expense	141.79	67.09	40.03	107.12	74.65
Other expenses	733.15	1,048.63	649.21	1,697.84	605.68
Total Expenses	3,765.43	4,386.25	3,307.91	7,694.16	4,627.17
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,111.09	2,118.66	1,532.71	3,651.37	1,460.73
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,111.09	2,118.66	1,532.71	3,651.37	1,460.73
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,111.09	2,118.66	1,532.71	3,651.37	1,460.73
X. Tax expense:					
(1) Current tax	486.90	375.12	370.65	745.77	361.15
(2) Income tax for earlier years		38.63		38.63	
(3) Deferred tax Liability / (Assets)	44.94	169.47	15.49	184.96	8.57
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,579.25	1,535.44	1,146.57	2,682.01	1,091.01
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	1,579.25	1,535.44	1,146.57	2,682.01	1,091.01
XVI. Earning per equity share:					
(1) Basic	8.71	8.49	8.14	16.65	9.70
(2) Diluted	8.71	8.49	8.14	16.65	9.70

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001 Sector 80 Noida U.P

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

UNAUDITED STANDALONE STATEMENT OF CASH FLOW AS AT 30 SEPTEMBER, 2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2025 (Audited)
Profit before tax	2,111.09	1532.71	3,651.37
Adjustments for:			
Depreciation & amortization expense	141.79	40.03	107.12
Interest expense on borrowings	231.37	181.32	348.27
Interest income	(35.94)	(7.22)	(10.65)
Provision for Gratuity			-
Preliminary exp written off			0.03
Operating Profit before working capital changes	**2,448.31**	**1,746.84**	**4,096.19**
Changes in operating assets and liabilities:			
Increase/(decrease) in trade payables	411.73	124.05	441.29
Increase/(decrease) in other current liabilities	20.32	131.22	59.10
Increase/(decrease) in Short Trem Borrowings	1,565.67	189.88	(580.54)
Increase/(decrease) in Short Trem Provisions	(55.88)	0.10	(319.05)
Increase/(decrease) in Long Trem Provisions	8.86	5.31	7.97
Decrease/(increase) in trade receivables	(1,022.72)	(1,660.94)	(2,138.37)
Decrease/(increase) in Inventory	(694.61)	(207.08)	(452.86)
Decrease/(increase) in Short Term loans and advances	(538.65)	(1,187.59)	(86.76)
Decrease/(increase) in Long Term loans and advances	(96.27)	-	(183.13)
Decrease/(increase) in other current assets	(229.25)	(85.85)	(143.20)
Decrease/(increase) in other Non-current assets	0.04	0.04	
Cash generated from operations	**(630.77)**	**(2,690.85)**	**(3,395.53)**
Income taxes refunded/ (paid)	1,817.54	(944.01)	700.66
Net cash flow from operations (A)	(68.64)	(309.13)	(321.79)
	1,748.90	**(1,253.13)**	**378.86**
Cash flow from investing activities			
Purchase of /Advances for property, plant & equipment and Intangible assets	(4,800.62)	(952.82)	(6,279.83)
Sale of property, plant & equipment			
Investment in Noncurrent Investment			
(Increase)/Decrease in other advance			
Interest received	35.94	7.22	10.65
Purchase of Fixed Assets in acquisition of Business			
Purchase of Investments in acquisition of Business			
Purchase of Advances in acquisition of Business			
Purchase of Trade Receivable in acquisition of Business			
Purchase of Inventories in acquisition of Business			
Purchase of Other Assets in acquisition of Business			
Purchase of Trade advances in acquisition of Business			
Purchase of Trade Payable in acquisition of Business			
Purchase of Other Liabities in acquisition of Business			
Purchase of Borrowings in acquisition of Business			
Purchase of Deferred Tax in acquisition of Business			
Purchase of Provisions in acquisition of Business			
Purchase of Cash & Cash Equivalents in acquisition of Business			
Less: Cash & Cash Equivalents			
Increase/(decrease) in Adavnce to subsidiary	(142.00)		127.01
Net cash used in investing activities (B)	**(4,906.69)**	**(945.60)**	**(6,142.17)**
Cash flow from financing activities			
Proceeds from issue of capital/equity shares			
Further issue of capital	95.82	479.30	479.30
Money received against share warrants	739.58		
Proceeds from share premium	9,006.76	6,470.55	6,470.55
Share issue expenses	(150.21)	(1,083.72)	(1,088.60)
Proceeds/(Repayment) of Long Term Borrowings	1,888.87	116.64	1,168.86
(Repayment)Receipt of borrowing	-		-
Interest paid	(231.37)	(181.32)	(348.27)
Net cash flow from/ (used in) financing activities (C)	**11,349.44**	**5,801.45**	**6,681.84**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	8,191.65	3,602.71	918.53
Cash and cash equivalents at the beginning of the year	954.10	25.56	35.56
Cash and cash equivalents at the closing of the year	**9,145.75**	**3,628.28**	**954.10**
Cash in hand	20.26	11.44	21.86
Balances with banks:			-
- On FDR			610.85
- on other than current acount	9,103.34		144.90
- On current accounts	22.16	3,616.84	176.49
Total	**9,145.75**	**3,628.28**	**954.10**

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001 Sector 80 Noida U.P

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-42171194 Mob : 9810247478
E-mail : jainchopra.company@gmail.com

Independent Auditor's Limited Review Report on unaudited consolidated financial results of Anondita Medicare Limited for the half year ended September 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015

To,
The Board of Directors of Anondita Medicare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Anondita Medicare Limited** ("**the Holding Company**") its subsidiary and associate (the Holding Company its subsidiary and associate together referred to as "**the Group**") and its share of the net profit/(loss) after tax for the half year ended September 30, 2026 of its associate ("**the Statement**"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

   A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

   The Statement includes the results of the following entities:

M/s Anondita Pharma and Latex Limited (Formerly known as- M/s Anondita Healthcare and Rubber Products India Limited)	Subsidiary
M/s Anondita Healthcare (Partnership Firm)	Associate

JAIN CHOPRA & COMPANY * NEW DELHI * CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in AS 25 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement includes the Group's share of net profit after tax of Rs. 633.06 lacs and Rs. 147.98 lacs for the half year ended September 30, 2026 and half year ended September 30, 2025 respectively as considered in the unaudited consolidated financial results, in respect of an subsidiary referred in para 4 above, whose interim financial statement has not been reviewed by us. This interim financial statement has been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

7. Our conclusion is not modified in respect of this matter.

For Jain Chopra & Company
Chartered Accountants
FR No. 002198N

Rajesh Kumar

Rajesh Kumar
Partner
M.No. 501860

JAIN CHOPRA & COMPANY ★ NEW DELHI ★ CHARTERED ACCOUNTANTS

Place: New Delhi
Date: 14-11-2026

UDIN: 26501860OPPUUW4961

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

Unaudited Consolidated Financial Statement as at September 30, 2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)
I. EQUITY AND LIABLITIES			
1. Shareholders' funds			
(a) Share Capital	1,904.48	1808.79	1,808.66
(b) Reservs and surplus	22,102.43	9053.54	11,115.06
(c) Minority Interest	272.99	134.39	203.22
(d) Money received against share warrants	739.58		-
2. Share application money pending allotment			-
			-
3. Non - current liabilities			-
(a) Long-term borrowings	4,272.89	1307.40	2,387.03
(b) Deferred Tax Liability (net)	169.83	24.06	193.52
(c) Other Long term liabilities			-
(d) Long Term Provision	26.66	15.13	17.80
			-
4. Current liabilities			-
(a) Short-term borrowings	2,787.95	1773.29	973.12
(b) Trade payables			-
A) Total outstanding dues of micro enterprises and small enterprises	164.22	153.00	141.23
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,066.17	484.05	661.56
(c) Other current liabilities	294.76	323.39	248.79
(d) Short-term Provisions	1,377.09	974.38	733.14
Total	**35,179.05**	**16,051.43**	**18,483.12**
ASSETS			
1) Non Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	5,297.19	1277.25	3,909.76
(ii) Intangible assets			-
(a) Goodwill	19.18	19.18	19.18
(iii) Capital Work In Progress	7,420.55	1522.08	4,149.50
(iv) Intangible assets under development			-
(b) Non-current Investments	331.40	331.40	331.40
(c) Deferred tax assets (net)	0.25	0.22	0.24
(d) Long-term loans and advances	317.06	37.66	220.79
(e) Other non - current assets	0.12	0.24	0.16
			-
2) Current Assets			-
(a) Current investments			-
(b) Inventories	3,516.88	1450.10	2,075.01
(c) Trade receivables	6,002.32	4809.67	5,185.67
(d) Cash and Cash Equivalents	9,150.99	3650.96	965.19
(e) Short-term loans and advances	2,356.89	2127.18	1,114.56
(f) Other current assets	766.23	825.49	511.66
Total	**35,179.05**	**16051.43**	**18,483.12**

For & On behalf of the Board
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: 02675517
D-001, Sector-80 Noida-201305

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183

Unaudited Consolidated Statement of profit and loss as at September 30 ,2026

Amount in Rs.Lakhs unless stated otherwise

PARTICULARS	For Half Year Ended			For Year ended	
	As at Sept 30,2026 (Unaudited)	As at March 31, 2026 (Audited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I. Revenue from operations	7,354.17	8,331.87	5,409.70	13,741.57	7,699.07
II. Other Income	60.48	43.46	40.78	84.24	13.88
III. Total Income (I +II)	7,414.64	8,375.33	5,450.48	13,825.81	7,712.95
IV. Expenses:					
Cost of Materials Consumed	2,775.47	2,867.91	2,353.22	5,221.13	3,376.69
Purchase of Stock-in-Trade	1,295.26	1,199.61	164.93	1,364.54	744.86
Change in inventories of finished goods, Work in progress and Stock in Trade	(1,277.67)	(500.33)	(79.18)	(579.51)	(293.20)
Employee benefit expense	461.46	484.75	348.10	832.85	686.80
Financial costs	242.28	171.45	182.35	353.80	291.09
Depreciation and amortization expense	142.15	67.21	40.87	108.09	75.79
Other expenses	830.33	1,133.47	702.49	1,835.95	618.70
Total Expenses	**4,469.28**	**5,424.07**	**3,712.78**	9,136.85	5,500.73
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,945.37	2,951.26	1,737.70	4,688.96	2,212.22
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,945.37	2,951.26	1,737.70	4,688.96	2,212.22
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,945.37	2,951.26	1,737.70	4,688.96	2,212.22
X. Tax expense:					
(1) Current tax	699.83	594.87	420.42	1,015.29	553.25
(2) IncomeTax for Earlier years		59.08	-	59.08	-
(3) Deferred tax Liability / (Assets)	44.93	169.45	15.49	184.94	8.50
XI. Profit(Loss) for the year from continuing operations (IX - X)	2,200.60	2,127.86	1,301.79	3,429.65	1,650.47
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	2,200.60	2,127.86	1,301.79	3,429.65	1,650.47
Profit for the Year attributable to					
a. Owners of the Company	2,130.83	2,059.04	1,285.56	3,344.60	1,588.21
b. Minority Interest	69.78	68.82	16.23	85.06	62.26
XVI. Earning per equity share:					
(1) Basic	11.76	11.38	9.08	20.77	14.11
(2) Diluted	11.76	11.38	9.08	20.77	14.11

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001, Sector-80 Noida-201305

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183

Unaudited Consolidated Statement of Cash Flow as at September 30 ,2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)
Profit before tax	2,945.37	1,737.70	4,688.96
Adjustments for:			
Depreciation & amortization expense	142.15	40.87	108.09
Interest expense on borrowings	242.28	247.33	353.80
Interest income	(6.20)	(7.22)	(10.65)
Loss on sale of Car			-
Provision for Gratuity			-
Preliminary exp written off	0.04		0.12
Operating Profit before working capital changes	**3,323.64**	**2,018.68**	**5,140.32**
Changes in operating assets and liabilities:			
Increase/(decrease) in trade payables	427.60	255.52	421.26
Increase/(decrease) in other current liabilities	45.97	113.33	38.72
Increase/(decrease) in Short Trem Provisions	(55.88)	0.10	(511.16)
Increase/(decrease) in Long Trem Provisions	8.86	5.31	7.97
Decrease/(increase) in trade receivables	(816.65)	(2,134.34)	(2,510.34)
Decrease/(increase) in Inventory	(1,441.88)	(99.33)	(717.00)
Decrease/(increase) in Short Term loans and advances	(1,242.33)	(454.33)	(163.95)
Decrease/(increase) in Long Term loans and advances	(96.27)	-	(183.13)
Decrease/(increase) in other current assets	(254.57)	(93.01)	(116.66)
Decrease/(increase) in other Non-current assets	-	0.04	-
	-		
	(3,425.15)	**(2,406.71)**	**(3,734.27)**
Cash generated from operations	(101.51)	(388.03)	1,406.05
Income taxes refunded/ (paid)	(68.64)	(309.13)	(342.24)
Net cash flow from operations (A)	**(170.14)**	**(697.15)**	**1,063.81**
Cash flow from investing activities			
Purchase of /Advances for property, plant & equipment and Intangible assets	(4,800.62)	(953.55)	(6,280.69)
Sale of property, plant & equipment			
Investment in Noncurrent Investment			
(Increase)/Decrease in other advance			
Interest received	6.20	7.22	10.65
Purchase of Fixed Assets in acquisition of Business			
Purchase of Investments in acquisition of Business			
Purchase of Advances in acquisition of Business			
Purchase of Trade Receivable in acquisition of Business			
Purchase of Inventories in acquisition of Business			
Purchase of Other Assets in acquisition of Business			
Purchase of Trade advances in acquisition of Business			
Purchase of Trade Payable in acquisition of Business			
Purchase of Other Liabities in acquisition of Business			
Purchase of Borrowings in acquisition of Business			
Purchase of Deferred Tax in acquisition of Business			
Purchase of Provisions in acquisition of Business			
Purchase of Cash & Cash Equivalents in acquisition of Business			
Less: Cash & Cash Equivalents			
Net cash used in investing activities (B)	**(4,794.43)**	**(946.33)**	**(6,270.04)**
Cash flow from financing activities			
Proceeds from issue of capital/equity shares			
Further Issue of Capital	95.82	479.30	479.30
Money received against share warrants	739.58		
Share Premium	9,006.76	6,470.55	6,470.55
Share Issue Expense	(150.21)	(1,083.72)	(1,088.61)
Proceeds/(Repayment) of Long Term Borrowings	1,885.86	116.64	1,196.26
Increase/(decrease) in Short Trem Borrowings	1,814.84	(473.95)	(575.22)
Interest paid	(242.28)	(247.33)	(353.80)
Net cash flow from/ (used in) financing activities (C)	**13,150.36**	**5,261.50**	**6,128.48**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	8,185.78	3,618.02	922.25
Cash and cash equivalents at the beginning of the year	965.21	32.94	42.94
Cash and cash equivalents at the closing of the year	**9,150.99**	**3,650.96**	**965.19**
Cash in hand	23.34	15.18	25.24
Balances with banks:			
- On FDR			600.11
- on other than current acount	9,103.34		155.64
- On current accounts	24.32	3,635.78	184.20
Total	**9,150.99**	**3,650.96**	**965.19**

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001, Sector-80 Noida-201305

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Subject: **Statement of deviation or variation in the use of proceeds of Initial Public Offering under Regulation 32 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that there has been no deviation/variation in the utilization of the proceeds from the Initial Public Offering as compared to the objects stated in the Prospectus as indicated in the Monitoring Agency Report submitted by Infomerics Valuation and Rating Limited dated November 14, 2026.

A Statement of Deviation or Variation for the half year ended September 30, 2026, duly reviewed by the Audit Committee and the Board of Directors at their meeting held on, i.e., November 14, 2026, is enclosed herewith as Annexure-A.

The above information is also being uploaded on the website of the Company.

Kindly take the above information on your records.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Anondita Medicare Limited
Mode of Fund Raising	IPO (Initial Public Offer)
Date of Raising Funds	28th August, 2025
Amount Raised	6949.85 Lakhs
Report filed for Quarter/ Half Year Ended	Half Year ended
Monitoring Agency	Yes
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	No deviation or variation has been reported by the Monitoring Agency in the utilisation of IPO proceeds.
Comments of the Audit Committee after review	The Audit Committee has reviewed the Monitoring Agency Report and noted that no deviation or variation has been reported in the utilisation of IPO proceeds.
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have not observed any deviation or variation in the utilisation of IPO proceeds from the objects stated in the Prospectus.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	**Modified Object, if any**	**Original Allocation(in Lakhs)**	**Modified allocation, if any (in Lakhs)**	**Funds Utilised (in Lakhs)**	**Amount of Deviation/Variation for the quarter according to applicable object**	**Remarks if any**
Funding Working Capital Requirements	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company's working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs. Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company's expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of ₹100 crore for FY 2025–26, which has now been revised to approximately ₹145 crore.	3500.00	3778.41	3778.41	NA	No deviation reported by the Monitoring Agency.
General Corporate Purpose (GCP)	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds allocated for Object 3 (Unidentified Acquisition and General Corporate Purposes) will to be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of	2015.87	1737.46	1737.46	NA	No deviation reported by the Monitoring Agency.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

	GCP Limit will be transferred towards meeting the Company's working capital requirements. No unidentified acquisition will be undertaken using the IPO proceeds. Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company's working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs. Further, while the utilization of these funds was initially projected over FY 2025–26 and FY 2026–27 and it was expected that the entire allocation was expected to be deployed within FY 2025–26 and yet the balance utilization will be made in this Financial year 2026-27.					
Capex	No variation in object of the issue except changes and/or additions to vendors, as disclosed in the Prospectus	600.00	NA	600.00	NA	No material deviation reported by the Monitoring Agency.
Issue expenses	NA	833.13	NA	833.13	NA	No deviation reported by the Monitoring Agency.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27, Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Subject: **Statement of deviation or variation in the use of proceeds of Right Issue under Regulation 32 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that there has been no deviation/variation in the utilization of the proceeds from the Right Issue as compared to the objects stated in the Letter of Offer as indicated in the Monitoring Agency Report submitted by Infomerics Valuation and Rating Limited dated November 14, 2026.

A Statement of Deviation or Variation for the half year ended September 30, 2026, duly reviewed by the Audit Committee and the Board of Directors at their meeting held on, i.e., November 14, 2026, is enclosed herewith as Annexure-A.

The above information is also being uploaded on the website of the Company.

Kindly take the above information on your records.
For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301



Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Anondita Medicare Limited
Mode of Fund Raising	Right Issue
Date of Raising Funds	24th September, 2026
Amount Raised	₹9,102.58 Lakhs.
Report filed for Quarter/ Half Year Ended	Half Year ended
Monitoring Agency	Yes
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	No funds were utilised out of the proceeds raised through the Rights Issue up to September 30, 2026. Accordingly, no deviation or variation has arisen during the reporting period.
Comments of the Audit Committee after review	The Audit Committee has reviewed the statement and noted that no funds were utilised out of the Rights Issue proceeds up to September 30, 2026.
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have observed that no funds were utilised out of the Rights Issue proceeds up to September 30, 2026. Accordingly, no deviation or variation in the utilisation of proceeds has arisen during the reporting period.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (in Lakhs)	Modified allocation, if any (in Lakhs)	Funds Utilised (in Lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Funding Working Capital Requirements	NA	2574.96	NA	NIL	NA	No deviation reported by the Monitoring Agency.
General Corporate Purpose (GCP)	NA	981.46	NA	NIL	NA	No deviation reported by the Monitoring Agency.
Capex	NA	5000.00	NA	NIL	NA	No material deviation reported by the Monitoring Agency.
Issue Related Expenses	NA	546.16	NA	NIL	NA	No deviation reported by the Monitoring Agency.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Subject: **Statement of deviation or variation in the use of proceeds of Preferential Issue** of **Convertible warrants under Regulation 32 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that there has been no deviation/variation in the utilization of the proceeds from the Preferential Issue of Convertible warrants to promoter category, as compared to the objects stated in the Notice of Extra Ordinary General Meeting along with the Explanatory Statement dated May 28, 2026.

A Statement of Deviation or Variation for the half year ended September 30, 2026, duly reviewed by the Audit Committee and the Board of Directors at their respective meeting held on, i.e., November 14, 2026, is enclosed herewith as Annexure-I.

Further, a certificate issued by the Statutory Auditors pursuant to NSE Circular No. NSE/CML/2024/23 dated September 05, 2024, in respect of the utilisation of funds raised through the Preferential Issue of Convertible Warrants into Equity Shares of Anondita Medicare Limited, is enclosed herewith as **Annexure II**.

The above information is also being uploaded on the website of the Company.

Kindly take the above information on your records.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms


STATEMENT OF DEVIATION / VARIATION IN UTILIZATION OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE- SHARE WARRANT

Name of listed Entity	Anondita Medicare Limited
Mode of Fund Raising	Preferential Issue of Convertible warrants to promoter category
Date of Issuance of Offer document	29-06-2026
Date of Raising Funds / Date of Allotment	08-07-2026
Total Amount of fund raised in the preferential issue	Rs 29,58,30,000 out of which Rs 7,39,57,500 (being 25% of the Warrant Issue Price) was received pursuant to allotment of Warrants dated 08-07-2026 and the balance 75% shall be receivable upon exercise of the Warrants.
Report filed for half year ended	30th September, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	No deviation or variation has arisen during the reporting period.
Comments of the Audit Committee after review	The Audit Committee has reviewed the statement and noted that no deviation or variation in the utilisation of proceeds has arisen during the reporting period.
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have observed that no deviation or variation in the utilisation of proceeds has arisen during the reporting period.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

ANONDITA MEDICARE LIMITED

OBJECTS FOR WHICH FUNDS HAVE BEEN RAISED AND WHERE THERE HAS BEEN A DEVIATION, IN THE FOLLOWING TABLE:

Original Object	Modified Object, if any	Original Allocation (Rs. in lacs)	Modified allocation, if any (Rs. in lacs)	Fund Utilised (Rs. in lacs)	Unutilised (Rs. in lacs)	Amount of Deviation/Variation for the quarter according to applicable object (Rs. in lacs)	Remarks if any
Facility Establishment & Expansion, Product Development for International Markets, Digital Infrastructure, Technology Platforms, Brand Building, Marketing & Promotional Activities.	NA	*2958.30	NA	739.28	*2219.02	NA	NA

Note: **** Out of the total size of ₹2,958.30 Lakhs, ₹739.58 Lakhs (25%of Warrant Issue Price) has been received, out of which ₹739.28 Lakhs has been utilised and ₹0.29 Lakhs remains unutilised as on September 30, 2026. The balance 75%, amounting to ₹2,218.73 Lakhs, is receivable upon exercise of the Warrants. Accordingly, the total unutilised and receivable amount aggregates to ₹2,219.02 Lakhs.***

This is to certify that the above-mentioned information is true to the best of my knowledge and belief, according to the books and documents produced before me for verification.

Yours faithfully,
For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th qu

															Additional disclosure c relates to loans, in entity/subsidiary. Thes	
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial incurred to make or g corporate deposits, investme	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedn
1	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products Private Limited	AANCA1209M	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Rent & Maintenance	400	Approved			99.12	0	0		
2	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Loan		2500	Approved			1298.18	571.89	713.9	Loan	
3	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Loan		2500	Approved			1182.95	0	0		
4	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Interest received		2500	Approved			26.77	0	0		
5	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare & Rubber Products India Limited	AAVCA5587G	Subsidiary Company	Sale of goods or services		3500	Approved			510.56	332.47	617.05		
6	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare	ABXFA1571G	ENTITY UNDER COMMON CONTROL PROMOTER	Any other transaction	Car Rent Service Received	150	Approved			88.5	0	0		
7	Anondita Medicare Limited	ABACA3332M	Anondita Healthcare Products	AANCA1209M	ENTITY UNDER COMMON	Any other transaction	Corporate Guarantee	374	Approved			5.83	373.06	367.23		

			Private Limited		CONTROL PROMOTER											
8	Anondita Medicare Limited	ABACA3332M	Anupam Ghosh	AEQPG6875G	Promoter and Managing Director	Any other transaction	Personal Guarantee	400	Approved			6.18	400	393.82		
Total value of transaction during the reporting period												3218.09				